Methods: An IVIS ® Lumina II imaging system was used to detect bioluminescent T. brucei brucei GVR35 parasites in mice to evaluate parasite localisation and disease progression. Drug treatment was assessed using qualitative bioluminescence imaging and quantitative PCR.
Introduction
Human African trypanosomiasis (HAT), or sleeping sickness, is caused by the vector-borne protozoan parasites Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense, with the subspecies giving rise to different clinical features and progression of this multi-stage disease. Fewer than 8000 cases were reported in 2013, 1 but almost 70 million people are exposed to the risk of the parasite infection within the African continent every year. 2, 3 The disease manifests in two stages: (i) an early stage, which is often referred to as the haemolymphatic stage with parasites present in the blood, lymph and peripheral tissue, and (ii) a later 2 nd stage that follows invasion of the central nervous system. Early and late stages are treated by different anti-trypanosomal drugs. 4 Patients typically present with late stage HAT due to the nonspecific nature of early stage symptoms. However, chemotherapeutic intervention at the late stage is not straightforward, being limited by the requirement of hospitalisation for parenteral dosing and inherent drug toxicity. 5 Drug development has been slow, partially due to the length of in vivo testing that is involved. Two new compounds are in clinical trials (fexinidazole and SCYX-7158). Currently the mouse models involved in HAT drug development are either for the early stage of the infection, using the monomorphic line T. b. brucei Lister 427 (or a derivative), or for the late stage, using the 'gold standard' pleiomorphic strain T. b. brucei GVR35. 6 GVR35 is commonly used to study CNS infection and assess drug therapies for the late stage of the disease, as these trypanosomes cross the blood brain barrier and limit outbred mice to a survival time of 30 days post-infection. The standard drug relapse method follows a 180-day infection protocol. 7 Bioluminescence imaging can provide highly sensitive, non-invasive detection of parasite distribution in a mouse model that can be followed in a single animal for the entirety of the experiment and removes the need for extra animal groups for each time point. Parasites labelled with bioluminescent reporters that emit light in the blue and green part of the spectrum, have encountered problems with high levels of tissue absorption, resulting in poor signal detection in deep tissue. 8 By using red-shifted proteins, an improved level of signal can be detected as light absorption by tissues is minimised, therefore providing more sensitive parasite detection than traditional blood films. 9, 10 An initial bioluminescent model using green light-emitting luciferase expressed in GVR35 was developed to study HAT in a mouse model. 10 Further to the use of GVR35 LUC-2, a red-shifted bioluminescent T. b. brucei strain, GVR35 VSL-2, was developed. 9 This strain was shown to have a bioluminescence 1000-fold higher than the GVR35-LUC2 strain, with a much higher sensitivity that allows detection of 100 trypanosomes or fewer in vivo. 9 We describe here a highly sensitive bioluminescence model, utilising the GVR35 VSL-2 strain to evaluate trypanocidal compounds and to determine drug relapse earlier than the current 180-day 'gold-standard' model. In addition this system reduces the number of animals required in comparison to the wild-type model and is able to evaluate and give a dose response on drugs by 35 days postinfection. Overall, use of this improved system shortens experiments from 180 to 90 days, which could significantly enhance drug development for HAT.
Materials and Methods

Animals and Ethics
Female CD1 mice in range of 20-25 g (Charles River, Margate, UK) were housed in groups no larger than five in specific pathogen-free individually vented cages, and were fed ad libitum. All work was carried out under the approval of the UK Home Office Animals (Scientific Procedures) Act 1986 and the London School of Hygiene & Tropical Medicine Ethics Committee. ARRIVE guidelines are followed in this report 11 .
Parasites
The strains used were wild-type (WT) T. b. brucei GVR35 and the transfected T. b. brucei strains GVR35 VSL-2 and GVR35 LUC2. 9, 10 The wild-type produces a chronic infection in mice, 12 and was used to validate the bioluminescent transfected strain.
Infection
Mice were infected as per Kennedy et al with minor modifications. 6 To confirm CNS infection, ex vivo imaging of perfused brains was performed. Prior to imaging, 50 µL of 15 mg/mL luciferin was pipetted onto the brain and imaged using the settings as above.
Real-time quantitative PCR to determine parasite load.
Real-time quantitative PCR was used to determine parasite load in cardiac blood and perfused brain material, using a primer sequence to target the invariant surface glycoprotein (ISG-75).
DNA was extracted from whole brain homogenate and cardiac blood using Roche High Pure PCR template according to the manufacturer's instructions (Roche, Burgess Hill, UK) and quantified by Nanodrop (ThermoFisher Scientific, Loughborough, UK).
Standards for the gene ISG-75 were generated by conventional PCR from T. b. brucei GVR35-derived cDNA, followed by purification using the QIAquick PCR Purification Kit (Qiagen, Crawley, UK). Copy numbers were calculated based on the fragment length, and standards were used in subsequent assays to generate standard curves ranging from 10 8 copies to 10 copies/reaction. The Neuropathological evaluation
The severity of the pathological reaction within the brain of mice infected with GVR35 WT was evaluated and compared with the VSL-2 strain as well as the recently described LUC2 strain. 10 This was carried out to ensure that there were no overt differences in neuropathogenesis between the genetically modified strains and the WT parasite. The mice were euthanized at 7, 14, 21 and 28 days post-infection and the brains were extracted and fixed in 4% neutral buffered formalin. The tissue was then embedded in paraffin wax, sectioned and stained with haematoxylin and eosin (H&E). The severity of the reaction was assessed by two independent assessors in a blinded fashion using a previously defined grading scale. 6 In vivo drug efficacy and relapse evaluation Mice were infected as described above. A CNS control group treated with analytical grade diminazene aceturate, DA (Sigma-Aldrich, Poole, UK) at 40 mg/kg intraperitoneally, which clears peripheral parasitaemia, and a negative control group of untreated infected mice was included for both strains. Mice were randomised into groups of five with a single group per drug/dose.
Melarsoprol is difficult to dissolve for administration, therefore, with advice from Pharmidex To assess relapse, two doses (10 mg/kg and 6 mg/kg) from the drug efficacy experiment were used and following the same protocol as described above, mice were infected and dosed. Mice were imaged and blood films (from the tail vein) taken every 7 days from D35 to D180. Mice were culled when humane endpoints (weight loss greater than 10% total body weight and hind-leg paralysis) of the experiment were reached.
Results
Validation of bioluminescence model
To ensure that the VSL-2 model exhibits the same kinetics of infection as the wild type GVR35, a direct comparison between the two strains was carried out using the standard 35-day study as described by Kennedy. 13 At D7 post-infection bioluminescence signal was patchy throughout the mouse, but resided predominantly in the lower back region and lymph nodes (Fig. 1a) . The trypomastigotes continued to multiply and spread throughout the blood and lymphatic system and, on D14, signal was observed throughout the animal. By D21 a similar signal distribution was seen, although the bioluminescence was much higher, peaking at 1 x 10 8 photons/second. From the heat-map scale it can be seen that the liver/spleen area displays the highest bioluminescence (Fig. 1a) , providing further evidence that the lymphatic system is heavily infected.
Following treatment with DA at D21, overall bioluminescence in infected animals imaged at D28 was greatly reduced, with a focal signal found only in the head region, as the clearance of peripheral parasitaemia revealed possible CNS infection. By D35, the bioluminescence signal in the head region became more intense, as the cranial concentration of parasites appeared to increase, with a 10-fold increase in flux between D28 and D35. The control wild type mouse showed no bioluminescence.
Quantitation of total flux revealed that as the infection progressed the bioluminescence increased from 10 8 to just under 10 10 total flux until DA treatment was administered (Fig. 1b) . In comparison parasitaemia was not detectable via microscopy until D14 and then was undetectable following treatment with DA (Fig. 1b) . It remained undetectable until the end of the experiment at D35 despite bioluminescence signal clearly apparent in the head.
To confirm the presence of trypanosomes in brain tissue following whole animal imaging at D35, the mice were perfused to clear the tissue of blood, and brains were excised and imaged ex vivo (Fig. 1c) .
Bioluminescence was detectable in all VSL-2-infected mouse brains and was comparable to the signal seen in the head region of the respective intact mice at D35 (Fig. 1a) . In the brain of mouse 2, the signal was most prominent in the olfactory bulb of the brain whereas in mouse 1 and 3 the signal nonspecifically disseminated through the entire brain, with mouse 3 showing a high signal (red 'hot spot') in the cerebellum. The remainder of the infected group showed similarly non-specific distribution of bioluminescence in the brain (not shown).
Following ex vivo imaging, DNA was prepared from the perfused brains and quantitative PCR was used to determine the parasite load in each brain (Fig. 1c) . Comparing qPCR to bioluminescence signal, the total flux was representative of the number of trypanosomes present. The brain of mouse 3 had areas of higher flux and therefore had an overall higher quantity of trypanosomes present.
However, in the brains of mouse 1 and 2, despite showing differences in the distribution of parasites, a trend can be identified between parasite burden as determined by qPCR and bioluminescence. The control wild type-infected brain had no bioluminescence but high parasitaemia.
To determine whether parasite transfection had interfered with invasion and neuropathological effects in the brain, 6 a well-established neuropathology grading scale was used to assess the severity of the neuropathological response over the course of infection of 28 days (Fig. 2) . VSL-2 was compared to the current bioluminescence model LUC2 and to WT. The results show that there was no significant difference between the neuropathological response to infection for the VSL-2 and wild type strains.
Drug efficacy of melarsoprol in the treatment of T. b. brucei GVR35 VSL-2
To extend the potential of a drug evaluation model, the ability to determine dose response, as well as relapse could provide an improved knowledge of drug efficacy. Infected mice were treated with melarsoprol at varying doses as indicated to provide a dose response and at D21, 24, 28, 30 and 35, bioluminescence and parasitaemia were measured (Fig. 3) . The bioluminescence and parasitaemia fell (Fig. 3b) immediately after treatment (D24 post-infection). Mice treated with 1 mg/kg melarsoprol, demonstrated an immediate clearance after treatment but, by D30, bioluminescence signal was detectable and was focused to the head and spinal region of the mouse (Fig. 3a) . The bioluminescence continued to increase and at D35 reached 100-fold greater than background (as determined by the average bioluminescence obtained from WT mice) at 10 8 photons/second and was disseminated throughout the entire animal. Although bioluminescence was detectable from D30 in the low dose melarsoprol treatment, peripheral parasitaemia could only be detected in these mice when the infection re-disseminated throughout the animals at D35 (Fig. 3a, b) .
A single 40 mg/kg dose of DA showed an initial drop in bioluminescence, with signal limited to the head region (as shown in Fig. 1a ) before increasing over the remaining 11 days (Fig. 3b) . Unlike the low dose melarsoprol-treated mice, peripheral parasitaemia was undetectable in blood films, suggesting the signal originated from organs or the lymphatic system. No recovery of bioluminescence was seen in mice treated at higher doses of melarsoprol within this time course.
At D35 mouse brains were removed and qPCR analysis carried out to determine the quantity of trypanosomes present after drug treatment. The detection limit of the qPCR was 50 trypanosomes/50 ng of DNA. A clear dose-response effect was observed (Fig. 3c) , with the increasing dose of melarsoprol reducing the number of trypanosomes present to below the detection limit. DA showed a high number of trypanosomes in the brain although with a reduction in parasite load compared to the untreated control, further confirming that DA was unable to clear parasites in the CNS to a curative level. The qPCR data of melarsoprol-treated brains correlates with the whole animal and ex vivo imaging data, and provides evidence that bioluminescence can be used to determine dose response effect.
Non-invasive monitoring of drug relapse
To investigate the potential of the VSL-2 model to study drug relapse, mice infected with GVR35 VSL-2 were treated with melarsoprol at curative (10 mg/kg) and non-curative (6 mg/kg) doses administered i.v. The bioluminescence and parasitaemia for each individual mouse was then followed through a 180-day study (Fig. 4) .
Parasitaemia for the mice dosed with 6 mg/kg (Fig. 4a) was undetectable prior to D63 in any animal, at which point low numbers of parasites were detectable in the blood of 4 of the 5 animals, after which parasitaemia increased. Mouse 5 remained aparasitaemic (according to blood films) during the 119 days showing few symptoms other than splenomegaly before being culled. In comparison, the bioluminescence data for this group of mice appears very different. Signal was detected as early as D49 for 3 of the 5 mice, and by D63 signal was observed in the remaining mice. Unlike the parasitaemia data for the same mice, the bioluminescence fluctuated during the 56-day period prior to the termination of the group at D119. Therefore, despite there being no detectable peripheral parasitaemia for mouse 5, bioluminescence was still detected in all mice in the 6 mg/kg group.
Immediately after treatment of 10 mg/kg melarsoprol, blood films indicated that the parasitaemia had cleared in all mice. Four of the five mice remained negative throughout the 180 days, but mouse 2 had parasitaemia at D91 of 14 trypanosomes/10 fields of view before decreasing and then reappearing again at D112 before being culled at D119 as the mouse became lethargic (Fig 4b) . In contrast, the bioluminescence data for 10 mg/kg shows that relapse occurred in mouse 2 much earlier, at D70 (Fig.   4b) , with a total flux of 4.64 x 10 6 photons/seconds (10-fold increase on the background) before falling below background detection, and then following a pattern of decreasing and increasing bioluminescence before a spike at D119 of 1.27 x 10 10 photons/second, when the mouse reached its humane endpoint. The bioluminescence approach was therefore able to detect drug relapse much earlier than traditional blood film.
Discussion
The current pre-clinical drug evaluation model requires mice to be monitored for up to 180 days postinfection, with relapse being detected when parasites re-establish an infection in the periphery, detectable in blood films. 6 This model is unable to detect viable parasites in other organs such as the brain, without mice being sacrificed and the tissues removed for further analysis. The experimental time period of six months is not appropriate for drug development and a new innovative approach is required to speed up the process and provide data on time-to-kill and differential effects on parasite distribution. At present there is no current model for assessing dose response drug efficacy, as it is not possible to determine the level of parasite persistence within tissues using contemporary techniques.
Bioluminescent model systems utilising luciferase have been described for the assessment of drugs for other diseases and infections. [14] [15] [16] The progress made with both the LUC2 model and development of the red-shifted VSL-2 strain, has paved the way for a new mouse model of HAT that is both highly sensitive and non-invasive. Preliminary studies on GVR35 VSL-2 showed that the model produces similar infection to the wild type strain and that bioluminescence can be detected in the brain by both whole animal and ex vivo imaging.
9
VSL-2 provides higher imaging sensitivity than previous transfected trypanosome strains, 9,10 and it is this that enables a dose-response effect to be detected in whole mouse imaging after treatment with melarsoprol. While the LUC2 model provided a substantial improvement on the currently used GVR35 wild type model, 10 the greater sensitivity and detection limit of the VSL-2 model as determined in this study allows bioluminescence to be used to determine a dose response effect, and analysis of excised brains using PCR corroborates this. Furthermore, the i.v. infection route provides a (mouse 2) it was clear from the bioluminescence that parasites could persist long after treatment with increasing flux around D60 and then again at D81 to D112 suggesting relapse. Early studies on melarsoprol also showed that the regimen of 10 mg/kg x 3 days i.v., gave no relapse in peripheral parasitaemia detected by blood films, but two-thirds of the mice in the study died. 17 Poltera concluded that melarsoprol was curative as no parasites were found in the circulating blood or brain tissue in all of the mice as determined by histopathological study and immunofluorescence. 17 The data we have shown here supports that peripheral parasitaemia was not detected, but bioluminescence re-emerged after treatment in one of the five mice through the 180 day experiment, lending further evidence that the lymphatic system is involved in parasite invasion and also raises question on how 'cure' can be defined in the mouse model.
In summary, we have presented evidence here that the red-shifted bioluminescent GVR35 VSL-2 model has the capability of providing a far more sensitive drug assessment system by non-invasive imaging, with the ability to reduce initial screening time by 120 days. In addition to this, the high sensitivity of the imaging combined with quantitative methods of qPCR, have allowed a new methodology to be developed that can assess drug efficacy in terms of ED 50 and ED 90 values of novel drugs for treatment of late stage of human African trypanosomiasis. The overall reduction in drug evaluation time and more comprehensive data that can now be determined for pre-clinical drugs will speed up drug development and aid the ongoing progress to HAT elimination. were manually altered to 1 in the parasitaemia counts to enable plotting on a logarithmic scale.
